Strategic partnerships Radiopharm Theranostics has recently signed a clinical supply agreement with Siemens Healthineers for a planned U.S. Phase 3 registrational trial, indicating openness to collaboration with large medical technology players and potential opportunities for co-development, manufacturing support, and distribution partnerships.

Clinical momentum The company is advancing its HEAT trial evaluating 177Lu-RAD202 in HER2-targeted radiopharmaceutical therapy, with data presentations at major conferences like AACR 2026, signaling a strong clinical roadmap that could attract CROs, trial service providers, and diagnostic imaging partners.

Funding surface Recent financing of AU$35M and a separate $22.7M funding round highlight available capital to accelerate pipeline activities, presenting an opportunity to engage investors, strategic partners, and service contractors aligned with radiopharmaceutical development.

Leadership & expertise Board and SAB enhancements, including a new Non-Executive Director and a renowned scientist on the advisory board, suggest a solid governance and scientific credibility that can be leveraged to attract high-level collaboration, licensing discussions, and sponsor-led programs.

Global visibility Active participation in international conferences and events (AACR, EMIM, TD Cowen) indicates a readiness to promote capabilities to a global audience, creating multiple touchpoints for potential customers, partners, and contract research/production opportunities.